| 5 | 1/1 | 返回列表 |
| 查看: 852 | 回復(fù): 2 | ||
| 當(dāng)前只顯示滿足指定條件的回帖,點(diǎn)擊這里查看本話題的所有回帖 | ||
小木蟲(chóng)劉樹(shù)青木蟲(chóng) (著名寫(xiě)手)
夜未眠
|
[求助]
求大神翻譯 只有一段哦,謝謝
|
|
|
In the future, it is likely that ctDNA and CTCs will have complementary roles as cancer biomarkers although separate approaches may have distinct advantages in specificclinicalcontexts. ctDNA analysis is appealing due to the ease with which plasma can be collected and analyzed without the prior need to enrich and isolate a rare population of cells. For this reason, ctDNA analysis is likely to be the preferred option for genotyping and monitoring treatment response. The analysis of ctDNA can be applied as a high-throughput strategy for the assessment of clinical samples, but is limited to the analysis of point mutations, structural rearrangements, copy number aberrations and changes in DNA methylation. In contrast, the analysis of CTCs provides the unique opportunity to study the whole cell, allowing DNA, RNA and protein-based molecular profiling, and the opportunity for functional studies to guide personalized treatment selection. Although the analysis of both ctDNA and CTCs pose several technical challenges, ongoing improvements are expected over coming years, and both approaches hold great promise as biomarkers in various facets of cancer management. Technological advances might allow in the future, the use of a liquid biopsy (CTCs or ctDNA) for earlier cancer diagnosis or detection of disease relapse/progression. However, it is not known if earlier detection will lead to improved patient outcomes. This will become possible only if effective treatments are available to target early recurrences. Another open question is whether the liquid biopsy will complement analysis of primary tumor or metastases for tailoring treatment selection. Ongoing interventional clinical trials using CTC detection and characterization by CellSearch® will provide initial answers on the above question. Future research will be focused on optimizing and standardizing new technologies for both ctDNA and CTC analysis, demonstrating appropriate analytical and clinical validity as well as establishing the clinical utility of ctDNA and CTC testing through appropriately designed prospective clinical trials. |

金蟲(chóng) (正式寫(xiě)手)
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求調(diào)劑 +6 | 十三加油 2026-03-21 | 6/300 |
|
|---|---|---|---|---|
|
[考研] 324求調(diào)劑 +6 | lucky呀呀呀鴨 2026-03-20 | 6/300 |
|
|
[考研]
|
2117205181 2026-03-21 | 7/350 |
|
|
[考研] 生物學(xué)調(diào)劑 +5 | Surekei 2026-03-21 | 5/250 |
|
|
[考研] 一志愿北京化工大學(xué)070300 學(xué)碩336求調(diào)劑 +5 | vv迷 2026-03-21 | 8/400 |
|
|
[考研] 280求調(diào)劑 +11 | 咕嚕曉曉 2026-03-18 | 12/600 |
|
|
[考研] 考研調(diào)劑 +3 | 呼呼?~+123456 2026-03-21 | 3/150 |
|
|
[考研] 0805 316求調(diào)劑 +3 | 大雪深藏 2026-03-18 | 3/150 |
|
|
[考研] 311求調(diào)劑 +3 | 勇敢的小吳 2026-03-20 | 3/150 |
|
|
[考研] 299求調(diào)劑 +5 | shxchem 2026-03-20 | 7/350 |
|
|
[考研] 265求調(diào)劑 +12 | 梁梁校校 2026-03-19 | 14/700 |
|
|
[考研] 332求調(diào)劑 +3 | 鳳凰院丁真 2026-03-20 | 3/150 |
|
|
[考研] 求調(diào)劑 +6 | Mqqqqqq 2026-03-19 | 6/300 |
|
|
[考研] 材料工程(專)一志愿985 初試335求調(diào)劑 +3 | hiloiy 2026-03-17 | 4/200 |
|
|
[考研] 085410人工智能專碩317求調(diào)劑(0854都可以) +4 | xbxudjdn 2026-03-18 | 4/200 |
|
|
[考研]
|
不想起名字112 2026-03-19 | 3/150 |
|
|
[考研] 生物學(xué)調(diào)劑招人。! +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|
[考研] 312求調(diào)劑 +8 | 陌宸希 2026-03-16 | 9/450 |
|
|
[考研] 材料,紡織,生物(0856、0710),化學(xué)招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
[考研] 一志愿南京大學(xué),080500材料科學(xué)與工程,調(diào)劑 +4 | Jy? 2026-03-16 | 4/200 |
|